Impairment Risk Relating to Goodwill, Distribution Rights and Trademark Rights
First written in FY2016. 17 of 21 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2019: 5 of 13 companies on the "Worse" side.
10 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「Of the above amount, the sales rights of ¥10,701,254 thousand and trademark rights of ¥7,639,854 thousand relating to certain products held by Tillotts Pharma AG were determined not to show any indication of impairment. Although generic drugs have been launched in some overseas countries, sales of the products have generally remained in line with the sales plan, and no significant deterioration was identified in the business environment underlying the sales plan during the fiscal year under review.」
Even after generic drugs were launched, sales of certain products remained generally in line with the plan, and it was determined that there were no indications of impairment of the sales rights or trademark rights during the fiscal year. - FY2024MaterialisedAnnual report
「During the fiscal year under review, the performance of Pharmaceutical Joint Stock Company of February 3rd was below its business plan, and the Company determined that its real value had declined significantly. Because the carrying amount of the shares of the associate was written down to their real value in the Company's separate financial statements, ¥476,992 thousand, representing goodwill amortization, was recognized as an extraordinary loss pursuant to Paragraph 32 of Accounting Standards Committee Report No. 7, Practical Guidance on Capital Consolidation Procedures in Consolidated Financial Statements, revised on 22 March 2024 by the Japanese Institute of Certified Public Accountants.」
Due to the Vietnamese subsidiary's failure to meet its performance targets, the shares of the associate were impaired, and goodwill amortization of ¥476,992 thousand was recognized as an extraordinary loss. - FY2023MitigatedAnnual report
「When making acquisitions, the Group conducts due diligence, including external assessments before the acquisition, deliberations by the Board of Directors and management meetings concerning the appropriateness of the acquisition, and follow-up aimed at realizing synergies after the acquisition, in order to ensure that acquisitions contribute to business development.」
In response to the risk of impairment of goodwill, sales rights and other assets, the Company has explicitly stated that it conducts pre-acquisition assessments, deliberations by the Board of Directors and management meetings, and post-acquisition follow-up. - FY2023-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2023-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2023-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2022-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2022-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2022-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2020-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2020-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2019RestatedAnnual report
「In addition, significant amounts of sales rights and trademark rights are recognized in the Group's consolidated balance sheet. As with goodwill, these intangible fixed assets must be periodically assessed for indications of impairment. If impairment is determined to have occurred, recognition of an impairment loss could have a material adverse effect on the performance and financial position of the Group.」
The risk of impairment of intangible fixed assets, including sales rights and trademark rights, in addition to goodwill continues to be disclosed. - FY2019-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2019-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2019-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2018-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2017RestatedAnnual report
「Consolidated subsidiaries that have become Group companies through acquisitions, including Tillotts Pharma AG, have made significant contributions to the Group's performance. However, if the future performance of these subsidiaries deteriorates due to various factors, impairment of goodwill could have a material adverse effect on the performance and financial position of the Group.」
The risk of impairment of intangible fixed assets, including sales rights and trademark rights, in addition to goodwill continues to be disclosed. - FY2017-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2017-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2017-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of impairment of goodwill, sales rights and trademark rights. - FY2016First statedAnnual report
「A significant amount of goodwill was recognized in the consolidated balance sheet following the acquisitions. If the future performance of these subsidiaries deteriorates due to various factors, impairment of goodwill could have a material adverse effect on the performance and financial position of the Group.」
Significant amounts of sales rights and trademark rights have also been recognized, including those acquired through the acquisition of rights to Entocort.